Literature DB >> 21178264

Serum thymidine kinase 1 activity in breast cancer.

Benjamin Nisman1, Tanir Allweis, Luna Kaduri, Bella Maly, Simon Gronowitz, Tamar Hamburger, Tamar Peretz.   

Abstract

AIMS: Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis and an important proliferation marker. We explored the association of preoperative serum TK1 activity with clinicopathological parameters and prognosis in terms of recurrence-free survival (RFS) in breast cancer (BC) patients. PATIENTS AND METHODS: TK1 activity in serum of 120 healthy women and 161 BC patients was measured by quantitative ELISA.
RESULTS: Serum TK1 activity in BC patients was significantly higher than in healthy women (P < 0.0001). In BC patients elevated TK1 activity was significantly associated with advanced T stage (P = 0.015), higher grade (P = 0.013), presence of tumor necrosis (P = 0.006), vascular invasion (P = 0.002), and lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P = 0.0004 and P = 0.003). Higher TK1 activity was found in patients with BRCA1/2 mutations compared to those without the mutation (P = 0.004). Multivariate Cox proportional hazards analyses demonstrated that TK1, adjusted for stage, grade, necrosis, ER and PR negativity was retained as an independent predictor of disease recurrence (Hazard Ratio = 3.9, 95%CI 1.3-11.6, P = 0.013).
CONCLUSION: Elevated serum TK1 is an important risk factor indicating a high proliferation potential of tumors at the time of excision. In multivariate analysis TK1 activity was found to be an independent prognostic factor for RFS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178264     DOI: 10.3233/CBM-2010-0148

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  17 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

Review 2.  Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.

Authors:  Erik S Knudsen; Geoffrey I Shapiro; Khandan Keyomarsi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

3.  Arabidopsis thaliana thymidine kinase 1a is ubiquitously expressed during development and contributes to confer tolerance to genotoxic stress.

Authors:  José Antonio Pedroza-García; Manuela Nájera-Martínez; María de la Paz Sanchez; Javier Plasencia
Journal:  Plant Mol Biol       Date:  2014-12-24       Impact factor: 4.076

4.  Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.

Authors:  M Bolayirli; C Papila; G G Korkmaz; B Papila; F Aydoğan; A Karataş; H Uzun
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

Review 5.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

6.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

7.  Thymidine kinase 1 upregulation is an early event in breast tumor formation.

Authors:  Melissa M Alegre; Richard A Robison; Kim L O'Neill
Journal:  J Oncol       Date:  2012-06-19       Impact factor: 4.375

8.  Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.

Authors:  Kiran Kumar Jagarlamudi; Lars Olof Hansson; Staffan Eriksson
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

9.  Identification of sample-specific regulations using integrative network level analysis.

Authors:  Chengyu Liu; Riku Louhimo; Marko Laakso; Rainer Lehtonen; Sampsa Hautaniemi
Journal:  BMC Cancer       Date:  2015-04-28       Impact factor: 4.430

Review 10.  Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.

Authors:  Alexandra J van den Broek; Marjanka K Schmidt; Laura J van 't Veer; Rob A E M Tollenaar; Flora E van Leeuwen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.